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Abstract
Background: Different international organizations recommend safety measures for the use of vincristine to prevent
wrong route administrations. A central recommendation is to use infusion bags instead of syringes to prevent confusion
with intrathecal chemotherapy. This study aimed to investigate the implementation of safety measures for vincristine and
intrathecal chemotherapies in Switzerland.
Method: We conducted a written survey among hospital pharmacies of all general care and pediatric hospitals in
Switzerland (n¼ 102). A responsible person of each hospital pharmacy was invited by email to participate in the
online survey in May 2018.
Results: Of 66 responding hospitals (response rate 65%), 27 have a hospital pharmacy preparing parenteral chemo-
therapy. All of these hospitals prepared vincristine in 2017, while 21 also prepared intrathecal chemotherapy. Of these
21, 16 hospitals prepared vincristine as syringes, with small volume syringes being the most widely distributed dosage
form. A switch from syringes to infusion bags was discussed in seven hospitals, and discussions led to plans for switch in
two. The most prevalent safety measures were labeling for vincristine and special delivery for intrathecal drugs. Of
hospitals preparing both vincristine syringes and intrathecal chemotherapy, four reported to have no safety measures
implemented neither for vincristine nor for intrathecal chemotherapy.
Conclusion: International recommendations are not widely implemented in Swiss hospitals. Syringes are still in use and
other safety measures are sparsely disseminated. Thus, Swiss vincristine patients are still at an increased risk for wrong
route application. Recommendations have to be further disseminated and implementation could be enhanced.
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Introduction
Over 100 cases of inadvertent intrathecal instead of
intravenous administration of vincristine have been
reported worldwide since vincristine is in use, with a
fatal outcome in the vast majority of patients.1–5
Invariably patients die or suﬀer considerable morbidity.
The reasons why these errors happened are not always
known. In a literature review, Gilbar et al. identiﬁed the
following possible reasons:
[. . .] mistaking vincristine for intended intrathecal
medication, mislabeling of syringes, i.v. and intrathecal
drugs brought into treatment area at the same time,
inexperienced medical staﬀ, patient not treated in a
specialist unit, treatment given out of normal hours,
administration order not checked and an incomplete
warning label.3
Diﬀerent organizations such as the World Health
Organization (WHO),2 the Institute for Safe
Medication Practices (ISMP),6 the International
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Society of Oncology Pharmacy Practitioners (ISOPP),7
the American Society of Clinical Oncology and the
Oncology Nursing Society8 and the German
Aktionsbu¨ndnis Patientensicherheit9 alert health care
professionals about the continued occurrence of
these errors and recommend safety measures for the
use of vincristine. A long-term recommendation is to
design and use administration material for vincristine
in a ‘‘lock and key’’ system that hinders connection of
i.v. material with spinal needles.2,9 Such material
would make inadvertent connections physically impos-
sible and seems to be used in some countries.
However, with the drug administration material cur-
rently used in Switzerland, connections are still pos-
sible. An important recommendation is to use infusion
bags of at least 50ml volume for infusion instead of
syringes for injection.2,6,7,9 Furthermore, only experi-
enced physicians should prescribe vincristine9 and an
experienced pharmacist should perform a plausibility
check before and another check after preparation.9
The vincristine preparations should be packaged
with types or color of material and labels other than
those used for standard preparations2,9 and delivered
to the administering unit in separate ways and at dif-
ferent time points from intrathecal drugs.9 Vincristine
should be administered by experienced staﬀ only
and its administration should occur at diﬀerent times
and in separate locations from intrathecal
administrations.9,10
These simple, but possibly life-saving recommenda-
tions however seem to be implemented to a limited
extent in practice.11–14 A survey in German university
hospitals published in 2010 showed that 76% of vin-
cristine preparations for a speciﬁc adults’ chemother-
apy protocol were still prepared as syringe, and special
labeling was missing in 92% of the surveyed hospitals.12
Except for this German survey, European countries are
poorly represented in the international studies investi-
gating the implementation of safety measures.10,13 No
data have so far been available if and how well the
above-mentioned recommendations are implemented
in Switzerland.
The goal of this study was to investigate the
implementation of internationally recommended
safety measures in Switzerland. This study in detail
aimed to investigate how frequently and in what
dosage forms vincristine is used in Swiss hospitals.
Furthermore, the implementation rates of recom-
mended safety measures for vincristine were evaluated.
Safety measures for intrathecal chemotherapies were
also taken into account, as they may play a role
in preventing vincristine to be confused for an intra-
thecal drug.
Methods
Survey
We conducted a written survey among Swiss
hospital pharmacies. Questions for the survey consisted
of open and closed questions, single and multiple
choice questions, and were based on international
literature.1,12 Quantities of vincristine used were
evaluated for the year 2017. If a pharmacy prepared
both for in-patient wards and ambulatory infusion
units, participants were asked to respond for in-patient
wards.
The survey draft was piloted by nine oncology or
chief pharmacists who were employed in the target
hospitals. Based on their feedback, minor adaptions
to the survey were made. The German survey was
then translated to French (Switzerland’s second most
common national language) by a bilingual oncology
pharmacist and checked by a French speaking scien-
tiﬁc collaborator and the primary investigator. The
survey (see supplementary material) was electronically
distributed in May 2018. Participants received an
email with an individualized link to the online
survey. A reminder was sent after three weeks and
the survey was closed four weeks after the ﬁrst
invitation.
Recruitment
Hospital pharmacies of all general care hospitals
(n¼ 102), and children’s hospitals (n¼ 3) according to
lists of the Swiss Federal Oﬃce of Public Health were
eligible for participation.15 The group of general care
hospitals consists of centralized tertiary care provided
by university and cantonal hospitals (cantons are
member states of the Swiss confederation) and of
basic local care provided by smaller, general care hos-
pitals.16 Specialized clinics were not included. The study
team aimed to gain contact information of the respon-
sible pharmacist of the hospital pharmacy, or, if not
available, another pharmacy staﬀ member. Contact
information was retrieved from the Swiss hospital
pharmacists’ association (GSASA) (n¼ 49) and the
missing contact information was completed by internet
search, by email or phone (n¼ 56). If one pharmacist
was responsible for several hospitals, the pharmacist
was invited separately for each hospital. Three persons
informed us that their two hospitals (each receiving a
separate invitation according to the list of 2016) now
belong to the same company and that only one invita-
tion would be appropriate. Three hospitals were
therefore excluded, resulting in a total population of
102 hospitals.
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Data analysis
Descriptive data analysis was conducted and an in-
depth analysis was performed for hospitals preparing
vincristine in their on-site hospital pharmacy. Only
completed surveys were included for the ﬁnal analysis.
Missing data were excluded case wise. Answers to the
‘‘other, namely:’’ option were recoded into one of the
multiple choice possibilities if clearly applicable.
In the survey, participants could choose whether or
not they have implemented diﬀerent safety measures
(e.g., special delivery). For each of the safety measures
implemented, a multiple choice question allowed
participants to select one or several diﬀerent speciﬁc
approaches used to implement the measure (e.g., trans-
portation container, delivery by speciﬁed staﬀ mem-
bers). Based on these questions, it was analyzed how
many hospitals implemented how many safety meas-
ures for vincristine and intrathecal therapies, irrespect-
ive of the speciﬁc approaches chosen. In addition, for
hospitals using both therapies, the numbers of safety
measures of both therapies were summed up.
The total of answers may not add up to 100% due to
rounding errors. Means are given with standard devi-
ation (SD) and medians are given with interquartile
ranges (IQR). To test associations, Fishers Exact-test
was used for categorical variables and Spearman cor-
relation was used for continuous variables. Statistical
signiﬁcance was set at 0.05.
The study was exempt from review (nihil obstat) by
the Ethics Committee of the Canton of Zurich (Req-
2018-0025).
Results
Characteristics
The characteristics of the participants and the corres-
ponding hospitals (66 of 102, response rate 65%) are
shown in Table 1.
Of the surveyed hospitals, 59 currently used paren-
teral chemotherapies, but preparation was organized in
diﬀerent ways (Table 1). The 27 hospitals with phar-
macy preparation were all four Swiss university hos-
pitals, 13 of 19 cantonal hospitals, nine of 37 general
hospitals, none of the three pediatric hospitals and one
of three hospitals of unknown type. In two pediatric
hospitals drugs were prepared by the administering
ward. The third pediatric hospital obtained their che-
motherapies from another hospital pharmacy.
Drug preparation
All 27 hospitals with an on-site hospital pharmacy pre-
paring parenteral chemotherapy did prepare vincristine
Table 1. Characteristics of participants and their correspond-
ing hospitals (n¼ 66a).
Chosen language of survey, n (%)
German 54 (82)
French 12 (18)
Participants’ gender, n (%)
Male 13 (20)
Female 52 (80)
Participants’ age (mean years standard deviation) 44 9
Participants’ profession, n (%)
Pharmacist 57 (86)
Physician 2 (3)
Nurse 3 (5)
Pharmacy technician 4 (6)
Participants’ position in hospital, n (%)
Head of pharmacy as technically
responsible personb
(e.g., pharmacist or physician)
23 (35)
Head of pharmacyb (without technical
responsibility, e.g., managing
pharmacy technician)
9 (14)
Head of chemotherapy productionb 23 (35)
Staff member in the chemotherapy production 3 (5)
Staff member in another pharmaceutical sector 3 (5)
Other 4 (6)
Hospital type, n (%)
University hospital 4 (6)
Cantonal hospital 19 (30)
General hospital 37 (59)
Pediatric hospital
(including university
pediatric hospitals)
3 (5)
Number of beds, n (%)
124 beds 23 (36)
125–499 beds 32 (50)
500 beds 9 (14)
Use of parenteral chemotherapy
in the hospital, n (%)
59 (89)
Preparation of parenteral chemotherapy,
n (% of answers)c
By on-site hospital pharmacy 27 (46)
By hospital pharmacy in other place 6 (10)
By administering ward 32 (54)
By other 2 (3)
aDue to missing data, not all questions sum up to 66 responses, bincluding
deputy, cmultiple choice question among those 59 hospitals using paren-
teral chemotherapy. Fifty-two hospitals (88%) indicated to have one prep-
aration site, six (11%) hospitals reported two sites and one hospital (2%)
reported three sites.
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in 2017. Pharmacies prepared a median of 112 (IQR 30,
210) vincristine doses for their on-site hospital, and 2.5
(IQR 1.5, 77) for other hospital companies. Twenty
pharmacies prepared vincristine for both ambulatory
infusion unit and in-patient wards, while six prepared
only for ambulatory infusion units and one only for in-
patient wards. Table 2 shows the diﬀerent vincristine
dosage forms used in 2017. Of 27 hospitals, 15 used
only syringes, six used only infusion bags and six used
both dosage forms.
Intrathecal chemotherapies were prepared in 21 of
27 hospital pharmacies in 2017, with a median of 25
(IQR 8, 120) doses.
Safety measures
Participants were surveyed about the safety measures in
place for vincristine and intrathecal chemotherapies.
Detailed answers on the implemented safety measures
and speciﬁc approaches chosen to implement them are
provided in Table 3. Figure 1 shows that four hospitals
had neither safety measures for vincristine nor for
intrathecal drugs prepared in their hospital. These
were one university, one general and two cantonal hos-
pitals. Two of these hospitals used only syringes for
vincristine, one only infusion bags and one both syr-
inges and infusion bags.
Having no versus at least one safety measure was not
associated with dosage forms, with the type of hospital
(both p¼ 1.0), the number of syringes and the number
of infusion bags prepared (correlation coeﬃcient
r¼0.02, p¼ 0.95 and r¼ 0.15, p¼ 0.66).
Of the participating hospitals, 12 already used infu-
sion bags for vincristine. Three of them had switched
from syringes to infusion bags within the two years
prior to the survey. All three hospitals indicated that
the initiative of the hospital pharmacy was the main
driver for the switch, and two hospitals additionally
indicated international guidelines as a driver. In 21 hos-
pitals with syringe use, seven had discussed a switch to
infusion bags. Main drivers for discussion were inter-
national (ﬁve cases) and national guidelines (two cases)
and the initiative of the hospital pharmacy (four cases).
At the time of the survey, two hospitals were planning
to switch. Main reasons that the switch was discussed
but not performed were suspected lower risk of extrava-
sation with syringes (three cases) and shorter adminis-
tration time with syringes (three cases). Stability of
diluted vincristine in normal saline was no issue. All
the seven discussing and two switching hospitals
belong to the 16 hospitals with syringe use for vincris-
tine and concomitant intrathecal chemotherapy
preparation.
When asked for (near) misses, one hospital indicated
a particular case of a confusion of vincristine and
methotrexate syringes with a fatal outcome. No further
information was asked or given on this case.
Discussion
To our knowledge, this is the ﬁrst survey on the safe use
of vincristine in Switzerland. Our results showed that
vincristine was frequently used in syringes, especially
when administering the drug to children. Diﬀerent
safety measures for vincristine have been implemented
to prevent wrong route application, most frequently
some special labeling. A relevant number of hospitals
have neither safety measures for vincristine nor for
Table 2. Vincristine dosage forms prepared in hospitals with on-site preparation by the hospital pharmacy.
Vincristine doses prepared Number of hospitals using the dosage form
For adults For children For adults For children
Syringe 9ml 1362 2 15 1
Syringe 10–19ml 276 284 4 2
Syringe 20–29ml 219 203 2 1
Syringe 30ml 0 0 0 0
Infusion bag 25ml 0 0 0 0
Infusion bag 26–49ml 0 0 0 0
Infusion bag 50–99ml 36 125 1 2
Infusion bag 100ml 1887 94 11 2
Other 20 0 1 0
Total syringes 1857 489
Total infusion bags 1923 219
Ratio syringes/infusion bags 0.97 2.23
Sum of all prepared doses and number of hospitals using the specific dosage form. Results are given for adults and children for the year 2017, n¼ 27.
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Table 3. Implementation of safety measures and the specific approach used.
Number of hospitals with that
safety measure in place
For vincristine
For intrathecal
preparations
Special prescription or approval by physician?a
Yesb 2 1
Only by certain physicians (e.g., seniors) 1 1
Only with signature of two physicians or by a different prescription
(e.g., special form)
0 0
Other 1 1
No 25 19
Special call up or order by nurses/wards?a
Yesb 3 5
Only by certain wards 2 1
Only by certain nurses, with signature of two nurses or different ordering
procedure (e.g., in writing instead of by telephone)
0 0
Other 1 4
No 24 15
Special checks in hospital pharmacy during preparation?
Yesb 3
For all vincristine preparations 1
Only for certain vincristine preparations 2
No 24
Provision with special administration material (e.g., bolus set, connecting tube,
transfer set, infusion set)?
Yesb 3
Material that could not be connected to a spinal needle 2
Material that could still be connected to a spinal needle 1
No 23
Special label on primary packaging (on syringe/infusion bag)?a
Yesb 6
Standard label
With specification of the administration route 4
With another information 2
Colored label, colored element on the label or other 0
Additional label
With specification of the administration route 1
Colored label 1
With another information or colored element on the label 0
Other 1
No or the same as for other chemotherapies 21
Label on secondary packaging (e.g., on outer bag, sealed transport bag)?
Yes 2
No 25
Different secondary packaging (e.g., material or color)?
Yes 0
No 27
(continued)
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intrathecal drugs, although some of them administered
vincristine in syringes, where a medication error is most
probable. Switches to infusion bags were discussed in a
minority of hospitals using syringes. Main drivers for
discussion were guidelines or the initiative of the hos-
pital pharmacists. A suspected lower risk of extravasa-
tion and a shorter administration time with syringes
where the main reasons to discard a switch.
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Figure 1. Number of safety measures. Number of hospitals with the respective number of safety measures for vincristine (n¼ 27),
intrathecal chemotherapies (n¼ 21) and summarized safety measures for both therapies where both therapies were prepared
(n¼ 21).
Table 3. Continued.
Number of hospitals with that
safety measure in place
For vincristine
For intrathecal
preparations
Special collection or delivery route?a
Yesb 2 8
On a different delivery route (e.g., personal collection) 0 5
In a special transport container (e.g., special box) 0 6
Only by certain wards (e.g., to prevent therapy from being delivered to wards
administering the other therapy)
1 0
To two different rooms within the same ward 0 2
Only by certain nurses (e.g., responsible nurse of the day) or at certain times
(e.g., to prevent other therapy being available at the same time)
0 0
Other 1 1
No 25 13
Only hospitals preparing vincristine in the on-site hospital pharmacy were included for questions on vincristine safety measures (column 1, n¼ 27c). Of
those, only hospitals with intrathecal preparations were asked for intrathecal safety measures (column 2, n¼ 21c). The number of hospitals having
reported one of the specific approaches used in a safety measure are also given for each safety measure.
aMultiple choice question.
bAny of the approaches below.
cDue to missing data, not all questions reach 27 or 21 answers.
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Comparison of findings with literature
Generally speaking, the main ﬁnding conﬁrms data
from other countries, namely the insuﬃcient compli-
ance with international recommendations for safe vin-
cristine use. However, some diﬀerences emerged. Our
sample consisted of general and pediatric hospitals,
whereof 46% have on-site pharmacy preparation. The
dissemination of pharmacy preparation corresponds to
international numbers, however in contrast to our data,
there are no literature reports on hospitals with more
than one preparation site.10,11 In our sample, 6 of
27 hospitals (22%) used exclusively infusion bags for
vincristine administration, which was lower than the
31% of hospitals reported in an international survey
conducted 2008.14 Many hospitals in our sample and
in literature have implemented use of infusion bags,
but have not yet completely substituted syringes.14
The ratio of syringes to infusions was 0.97 for adult
patients and 2.23 for children, although it should be
zero. The proportion of hospitals using infusion bags,
irrespective of whether or not they were also using
syringes, was lower in our study (44%) compared to
the two surveys of 2012 and 2014, each conducted in
diﬀerent countries (61 and 77%, respectively).10,13 The
ISMP-self assessment in 2012 also found implementa-
tion rates to be lower in European countries compared
to Australia or New Zealand.13
For Swiss adult patients, vincristine syringes are
mainly used in undiluted form, congruent with two
other studies.10,12 In these studies undiluted syringes
are also used for children. Swiss hospitals, in contrast,
use only diluted syringes for children, even though
volume restriction could be a clinical reason to use
small volumes under certain circumstances.6,9
As syringes should not be used for vincristine, we
examined how many of the hospitals using syringes
have discussed a switch. This was the case for 30% of
our sample, which is only half of the proportion
reported in an ISMP self-assessment.13 Thus, discus-
sions should be promoted and supported e.g., by pro-
viding fact sheets to practitioners. However, the reasons
why switches are not performed were similar in all stu-
dies. The fear of extravasation was a main barrier in
our sample and in literature,10,14 although extravasa-
tions are generally rare, even when using infusion
bags.17,18 Consistent with literature, longer infusion
duration was a barrier to switch in our study.10
We evaluated which diﬀerent safety measures are
implemented. Special prescription and order forms by
the physician and ordering by the nurses has not gained
much attention in the literature. However, we found
that some hospitals use special prescription or ordering
for vincristine and intrathecal chemotherapies.
Checking procedures are widely used in medication
processes, and checks to prevent wrong route applica-
tions of vincristine are implemented in 50–80% of hos-
pitals.10,11,14 In our sample, we found implemented
checks in only three of 27 hospitals, which were
checks during preparation, not before administration.
Labeling is a cheap to implement safety measure19
and it seems easy to add a special programmed warning
onto a label, e.g., ‘‘for i.v. use only – fatal if given by
other routes’’. This simplicity may explain why labeling
was one of the most frequent used safety measures in
our and other surveys.10,13,14 Still, labels and warnings
are rather weak safety actions as they solely rely on
human performance.20,21
Special delivery methods seem to be implemented fre-
quently for intrathecal chemotherapy in Switzerland.
However, delivery to diﬀerent units may be in place
due to organizational aspects of the medication pro-
cesses and not necessarily due to safety considerations.
Special delivery routes are also found to be frequent in
other countries,10,14 except for German university
hospitals.12
Overall, not many hospitals have more than one
safety measure implemented. But it has to be con-
sidered that not all safety measures are equally eﬀective,
according to the hierarchy of eﬀectiveness.20,21 A hos-
pital using infusion bag and non-connectable adminis-
tration material may target safety risks by systems
reliance and thus more eﬀectively than a hospital with
many labels, special communication processes, etc.
Implications for practice
Wrong route administrations of vincristine have been
known from the early years of the drug’s use in the
1960s.22 Despite ongoing publication of cases and rec-
ommendations, the health care system seems to be inert
to implement safety measures.10 Exceptions like a
recent publication reported successful implementa-
tion.23 A reason may be that vincristine and intrathecal
chemotherapy are not very common therapies, post-
poning the need for action on the everyday agenda
for improved medication safety. More importantly, rec-
ommended safety measures may be in opposition to
other priorities perceived by vincristine administering
staﬀ, i.e., avoiding extravasation and eﬃcient rou-
tines.10,14 Health care professionals may have the sub-
jective impression that other safety measures in place
are suﬃcient and overestimate the reliance on individ-
ual performance at the sharp end.14,20 A more system-
based approach however would address safety by
means of design or technical solutions, e.g., the use of
administration material for i.v. drugs that is not con-
nectable to spinal needles.2 However, the use of any
non-connectable material is still rare according to our
and other data.10,12 A possible reason for this is that the
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material is unavailable on their country’s market.22 The
recent dissemination of a system called ‘‘NRFit’’,
driven by an ISO-Standard 80369-6 (‘‘Connectors for
neuraxial applications’’) published in 2016 is a promis-
ing approach.24 Dissemination in Switzerland is
beginning.
Strengths and limitations
Surveying hospital pharmacists for such a research
question is an established method.10–12 The high
response rate of 65% overall and of 100% of the uni-
versity hospitals is a strength and may show the import-
ance of the subject for hospital pharmacies. We were
able to gain very detailed information on safety meas-
ures, speciﬁc approaches chosen and number of used
vincristine doses in Switzerland.
Some limitations have to be taken into account. No
specialized clinics were included and no in-depth infor-
mation on pediatric hospitals was gained. The data on
the use of vincristine were only obtained for hospitals
where the on-site pharmacy prepares parenteral chemo-
therapy. We assume that vincristine safety is highest in
these hospitals, possibly overestimating the safety on
the basis of our results. For methodological reasons,
safety measures are mainly reported for in-patient
wards. As a further limitation, pharmacy staﬀ may
not be aware of all safety measures used by speciﬁc
groups of staﬀ or on speciﬁc wards.
Within the survey, we had no focus on education
and training of hospital staﬀ. It is possible that special
training could be absent in Switzerland as it is in other
countries.11 However, the fact that pharmacists would
know the recommendations does not guarantee that
they would implement them.14
Conclusion
The results of the study show that compliance with
international recommendations to ensure safe vincris-
tine use in Switzerland is insuﬃcient. Patients are there-
fore still at an elevated and unjustiﬁable risk for wrong
route applications. With the knowledge of drivers and
barriers to switch from syringes to infusion bags, tar-
geted measures can be taken to support further hos-
pitals to perform the switch. When switching to
infusion bags, hospital pharmacists who play a key
role in provoking change should be engaged.
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